This mechanism enhances insulin secretion in response to meals, suppresses glucagon release, and slows gastric emptying
Direct IV NAD+ evidence remains preliminary, and compounded sterile NAD+ and glutathione products have quality and adverse-event concerns
Clinical trials have demonstrated significant reductions in hemoglobin A1c levels (approximately 1.52.0% from baseline) and substantial weight loss (averaging 1015% of body weight with higher doses)
Safety Considerations: Tirzepatide is not recommended for those with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, a history of pancreatitis, or severe gastrointestinal disease
Eligible Tampa patients may schedule a $79 consultation to discuss Tirzepatide, Zepbound, insurance coverage options, compounded tirzepatide programs, and physician-guided medical weight loss care